Analysts Set Sutro Biopharma, Inc. (NASDAQ:STRO) Target Price at $11.13

Sutro Biopharma, Inc. (NASDAQ:STRO) has received a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $11.13.

Several research firms recently commented on STRO. JMP Securities reaffirmed a “market outperform” rating and issued a $17.00 price target on shares of Sutro Biopharma in a research note on Wednesday, December 11th. Wedbush reaffirmed an “outperform” rating and set a $8.00 target price on shares of Sutro Biopharma in a research report on Tuesday, December 10th. Wells Fargo & Company lowered their price target on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating for the company in a report on Wednesday, December 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Sutro Biopharma in a research note on Monday, November 18th.

Sutro Biopharma Stock Up 4.7 %

STRO stock opened at $1.34 on Friday. The firm has a market cap of $110.50 million, a price-to-earnings ratio of -0.83 and a beta of 1.22. Sutro Biopharma has a twelve month low of $1.26 and a twelve month high of $6.13. The business’s fifty day simple moving average is $1.80 and its two-hundred day simple moving average is $2.80.

Hedge Funds Weigh In On Sutro Biopharma

Several institutional investors have recently bought and sold shares of STRO. SG Americas Securities LLC lifted its holdings in Sutro Biopharma by 16.6% during the fourth quarter. SG Americas Securities LLC now owns 40,432 shares of the company’s stock worth $74,000 after buying an additional 5,770 shares during the period. Rhumbline Advisers raised its position in shares of Sutro Biopharma by 6.1% in the 4th quarter. Rhumbline Advisers now owns 126,698 shares of the company’s stock worth $233,000 after acquiring an additional 7,320 shares in the last quarter. Gladius Capital Management LP bought a new position in shares of Sutro Biopharma in the 3rd quarter worth $28,000. Vontobel Holding Ltd. boosted its position in Sutro Biopharma by 66.7% during the fourth quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock valued at $46,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Wells Fargo & Company MN grew its stake in Sutro Biopharma by 24.8% in the fourth quarter. Wells Fargo & Company MN now owns 52,738 shares of the company’s stock valued at $97,000 after purchasing an additional 10,466 shares during the last quarter. 96.99% of the stock is owned by hedge funds and other institutional investors.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.